506 related articles for article (PubMed ID: 23363664)
1. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis.
Burt RK; Oliveira MC; Shah SJ; Moraes DA; Simoes B; Gheorghiade M; Schroeder J; Ruderman E; Farge D; Chai ZJ; Marjanovic Z; Jain S; Morgan A; Milanetti F; Han X; Jovanovic B; Helenowski IB; Voltarelli J
Lancet; 2013 Mar; 381(9872):1116-24. PubMed ID: 23363664
[TBL] [Abstract][Full Text] [Related]
2. Autologous HSCT for systemic sclerosis.
Sakellari I; Gavriilaki E; Mallouri D; Batsis I; Anagnostopoulos A
Lancet; 2013 Jun; 381(9883):2080. PubMed ID: 23769229
[No Abstract] [Full Text] [Related]
3. Autologous HSCT for systemic sclerosis.
van Laar JM; Nihtyanova SI; Naraghi K; Denton CP; Tyndall A
Lancet; 2013 Jun; 381(9883):2079-80. PubMed ID: 23769227
[No Abstract] [Full Text] [Related]
4. Improving safety in autologous HSCT for systemic sclerosis.
Snowden JA; Akil M; Kiely DG
Lancet; 2013 Mar; 381(9872):1081-3. PubMed ID: 23363663
[No Abstract] [Full Text] [Related]
5. Autologous HSCT for systemic sclerosis - Authors' reply.
Burt RK; Shah SJ; Schroeder J; Oliveira MC; Moraes DA; Simoes B; Marjanovic Z; Farge D
Lancet; 2013 Jun; 381(9883):2080-1. PubMed ID: 23769228
[No Abstract] [Full Text] [Related]
6. [Stem-cell transplantation in systemic sclerosis?--Cardiac health is decisive for the patient's benefit].
Riemekasten G
Dtsch Med Wochenschr; 2013 May; 138(21):1094. PubMed ID: 23677501
[No Abstract] [Full Text] [Related]
7. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.
Burt RK; Shah SJ; Dill K; Grant T; Gheorghiade M; Schroeder J; Craig R; Hirano I; Marshall K; Ruderman E; Jovanovic B; Milanetti F; Jain S; Boyce K; Morgan A; Carr J; Barr W
Lancet; 2011 Aug; 378(9790):498-506. PubMed ID: 21777972
[TBL] [Abstract][Full Text] [Related]
8. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.
Binks M; Passweg JR; Furst D; McSweeney P; Sullivan K; Besenthal C; Finke J; Peter HH; van Laar J; Breedveld FC; Fibbe WE; Farge D; Gluckman E; Locatelli F; Martini A; van den Hoogen F; van de Putte L; Schattenberg AV; Arnold R; Bacon PA; Emery P; Espigado I; Hertenstein B; Hiepe F; Kashyap A; Kötter I; Marmont A; Martinez A; Pascual MJ; Gratwohl A; Prentice HG; Black C; Tyndall A
Ann Rheum Dis; 2001 Jun; 60(6):577-84. PubMed ID: 11350846
[TBL] [Abstract][Full Text] [Related]
10. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis.
Oyama Y; Barr WG; Statkute L; Corbridge T; Gonda EA; Jovanovic B; Testori A; Burt RK
Bone Marrow Transplant; 2007 Sep; 40(6):549-55. PubMed ID: 17646844
[TBL] [Abstract][Full Text] [Related]
11. Optimization of autologous stem cell transplantation for systemic sclerosis -- a single-center longterm experience in 26 patients with severe organ manifestations.
Henes JC; Schmalzing M; Vogel W; Riemekasten G; Fend F; Kanz L; Koetter I
J Rheumatol; 2012 Feb; 39(2):269-75. PubMed ID: 22247352
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis.
Vonk MC; Marjanovic Z; van den Hoogen FH; Zohar S; Schattenberg AV; Fibbe WE; Larghero J; Gluckman E; Preijers FW; van Dijk AP; Bax JJ; Roblot P; van Riel PL; van Laar JM; Farge D
Ann Rheum Dis; 2008 Jan; 67(1):98-104. PubMed ID: 17526554
[TBL] [Abstract][Full Text] [Related]
13. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.
Sullivan KM; Goldmuntz EA; Keyes-Elstein L; McSweeney PA; Pinckney A; Welch B; Mayes MD; Nash RA; Crofford LJ; Eggleston B; Castina S; Griffith LM; Goldstein JS; Wallace D; Craciunescu O; Khanna D; Folz RJ; Goldin J; St Clair EW; Seibold JR; Phillips K; Mineishi S; Simms RW; Ballen K; Wener MH; Georges GE; Heimfeld S; Hosing C; Forman S; Kafaja S; Silver RM; Griffing L; Storek J; LeClercq S; Brasington R; Csuka ME; Bredeson C; Keever-Taylor C; Domsic RT; Kahaleh MB; Medsger T; Furst DE;
N Engl J Med; 2018 Jan; 378(1):35-47. PubMed ID: 29298160
[TBL] [Abstract][Full Text] [Related]
14. CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan.
Ayano M; Tsukamoto H; Mitoma H; Kimoto Y; Akahoshi M; Arinobu Y; Miyamoto T; Horiuchi T; Niiro H; Nagafuji K; Harada M; Akashi K
Arthritis Res Ther; 2019 Jan; 21(1):30. PubMed ID: 30670057
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience.
Henrique-Neto Á; Vasconcelos MYK; Dias JBE; de Moraes DA; Gonçalves MS; Zanin-Silva DC; Zucoloto TG; de Oliveira MFC; Dotoli GM; Weffort LF; Leopoldo VC; Oliveira MC
Adv Rheumatol; 2021 Feb; 61(1):9. PubMed ID: 33549135
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study.
van Bijnen S; de Vries-Bouwstra J; van den Ende CH; Boonstra M; Kroft L; Geurts B; Snoeren M; Schouffoer A; Spierings J; van Laar JM; Huizinga TW; Voskuyl A; Marijt E; van der Velden W; van den Hoogen FH; Vonk MC
Ann Rheum Dis; 2020 Aug; 79(8):1084-1089. PubMed ID: 32409324
[TBL] [Abstract][Full Text] [Related]
17. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus.
Burt RK; Traynor A; Statkute L; Barr WG; Rosa R; Schroeder J; Verda L; Krosnjar N; Quigley K; Yaung K; Villa Bs M; Takahashi M; Jovanovic B; Oyama Y
JAMA; 2006 Feb; 295(5):527-35. PubMed ID: 16449618
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: a systematic review of the literature.
Eyraud A; Scouppe L; Barnetche T; Forcade E; Lazaro E; Duffau P; Richez C; Seneschal J; Truchetet ME;
Br J Dermatol; 2018 Mar; 178(3):650-658. PubMed ID: 28906550
[TBL] [Abstract][Full Text] [Related]
19. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party.
Henes J; Oliveira MC; Labopin M; Badoglio M; Scherer HU; Del Papa N; Daikeler T; Schmalzing M; Schroers R; Martin T; Pugnet G; Simoes B; Michonneau D; Marijt EWA; Lioure B; Olivier Bay J; Snowden JA; Rovira M; Huynh A; Onida F; Kanz L; Marjanovic Z; Farge D
Haematologica; 2021 Feb; 106(2):375-383. PubMed ID: 31949011
[TBL] [Abstract][Full Text] [Related]
20. Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis.
Del Papa N; Onida F; Zaccara E; Saporiti G; Maglione W; Tagliaferri E; Andracco R; Vincenti D; Montemurro T; Mircoli L; Vitali C; Cortelezzi A
Bone Marrow Transplant; 2017 Jan; 52(1):53-58. PubMed ID: 27548467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
